Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.31 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 2/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL132502 | 0.78 | KIF11 (0.31) | — | |
| SCHEMBL28027917 | 0.77 | CYP2C19 (0.36) | CYP2C19HIF1ATSHRALDH1A1 | |
| Water SCHEMBL11440384 | 0.77 | — | — | |
| SCHEMBL692189 | 0.76 | KIF11 (0.32) | — | |
| SCHEMBL11152541 | 0.73 | KIF11 (0.34) | — | |
| SCHEMBL7598482 | 0.72 | MIF (0.33) | — | |
| SCHEMBL129231 | 0.72 | KCNN4 (0.36) | PTPN1CYP2C19HIF1ATSHRKCNN4 | |
| SCHEMBL15413 | 0.72 | KCNN4 (0.36) | PTPN1CYP2C19HIF1ATSHRKCNN4 | |
| SCHEMBL1149592 | 0.72 | KCNN4 (0.36) | PTPN1CYP2C19HIF1ATSHRKCNN4 | |
| SCHEMBL3517726 | 0.72 | KCNN4 (0.36) | PTPN1CYP2C19HIF1ATSHRKCNN4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7989449-B2 | 4,5-dihydro-oxazol-2-yl amine derivatives | HOFFMAN-LA ROCHE INC. (US) | 2011-08-02 | — | — | US | disclosed |
| US-20090209529-A1 | 4,5-DIHYDRO-OXAZOL-2-YL AMINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090209529-A1 | 4,5-DIHYDRO-OXAZOL-2-YL AMINE DERIVATIVES | BACE2, BACE1, PSEN2 | PTPN1 3897/4885CYP2C19 4317/4885HIF1A 3057/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.